Mar 29, 2026Cardiometabolic Health

GLP-1 Drugs and PAD: Better Walking, Unproven Amputation Prevention

GLP-1 drugs may improve walking in diabetes and PAD, but the headline 47% amputation reduction comes from weak observational evidence—not trials.

glp-1 agonistssemaglutideliraglutideperipheral artery disease

Read article →

Mar 28, 2026Cardiovascular Health

Tirzepatide and SGLT2 Inhibitors Show an AF Signal

Can tirzepatide and SGLT2 inhibitors reduce atrial fibrillation burden? New data link metabolic therapy to fewer AF procedures, but trials must confirm it.

tirzepatideatrial fibrillationglp-1 agoniststype 2 diabetes

Read article →

Mar 27, 2026Nutrition

Why NAD+ Supplements May Miss the Problem in Diabetic Hearts

New diabetic-heart research links ACMSD to impaired NAD+ synthesis, while the only heart-failure NAD+ trial leaves HFpEF treatment unanswered in humans.

nad+heart failurehfpefglp-1 agonists

Read article →

Mar 27, 2026Cardiovascular Health

GLP-1 Drugs and Heart Failure: What an NNT of 80 Means

GLP-1 drugs reduce heart failure events modestly overall, with stronger signals in obesity. See what the NNTs, limits, and next-generation drugs mean.

glp-1 agonistssemaglutidetirzepatideheart failure

Read article →

Mar 26, 2026Body Composition

GLP-1 Weight Loss: How Much Is Lean Mass?

A 2026 meta-analysis compares lean-mass loss on semaglutide, tirzepatide, and dieting—and shows why resistance training matters most.

semaglutidetirzepatideglp-1 agonistslean mass loss

Read article →

Mar 26, 2026Pharmacotherapy

SGLT2 vs GLP-1 Heart Protection Changes With Age

A large diabetes meta-analysis finds age may shift the relative heart benefit of SGLT2 inhibitors and GLP-1 drugs, while sex does not.

ozempicglp-1 agonistssglt2 inhibitorscardiovascular outcomes

Read article →

Mar 22, 2026Neuroprotection

Do GLP-1 Drugs Protect the Brain? The Evidence So Far

Do semaglutide and other GLP-1 drugs lower Parkinson's or Alzheimer's risk? Examine the observational signals, bias tests, and missing trial data.

glp-1 agonistssemaglutideparkinson's diseasealzheimer's disease

Read article →

Mar 21, 2026Metabolic Drugs

GLP-1 Heart Benefits: Blood Pressure Matters, But So Does Weight

GLP-1 drugs cut major cardiovascular events. Ambulatory monitoring suggests blood pressure gets more credit—but weight and direct effects still matter.

glp-1 agonistssemaglutideblood pressurecardiovascular outcomes

Read article →

Mar 21, 2026Glp1 Agonists

Do GLP-1 Drugs Raise Cancer Risk? What Trials Show

Do Ozempic, Wegovy, and Mounjaro raise cancer risk? Evidence from 48 trials and 94,245 patients finds no signal within 2–5 years.

liraglutideglp-1 agoniststhyroid cancersaxenda

Read article →

Mar 21, 2026Medication Safety

Do GLP-1 Drugs Raise Suicide Risk? What Trials Show

FDA and EMA reviews raised alarm about GLP-1 drugs and suicide. Placebo-controlled trials find no increased risk, but key gaps remain.

glp-1 agonistssemaglutidesuicidal ideationozempic

Read article →

Mar 21, 2026Diabetes Medications

Ozempic and Eye Risk: When Rapid A1c Drops Can Backfire

Can Ozempic worsen diabetic retinopathy? Evidence points to rapid A1c drops in people with existing disease, not a class-wide retinal toxin.

ozempicsemaglutidediabetic retinopathyglp-1 agonists

Read article →

Mar 19, 2026Nutrition

GLP-1 Drugs for Teens With Obesity: What the Trials Show

Do GLP-1 drugs help teens with obesity? Pediatric trials show lower BMI and risk markers, but long-term safety, rebound, and growth data remain unknown.

glp-1 agonistssemaglutidepediatric obesityweight loss

Read article →

Page 1 of 2Next →